GW Pharmaceuticals plc (NASDAQ:GWPH) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to GW’s investigational product Epidiolex® (cannabidiol or CBD) in the treatment of Lennox-Gastaut Syndrome (LGS), a treatment-resistant, debilitating childhood-onset epilepsy. “Following two positive Phase 3 trials of Epidiolex in patients with LGS, GW is committed to pursuing registration of Epidiolex in Europe in order to provide these patients access to an approved prescription CBD medicine,” stated Justin Gover, GW’s Chief Executive Officer. “In addition to preparing to submit a New Drug Application with the U.S. Food and Drug Administration in the middle of 2017, we are also planning a submission to the EMA shortly afterwards.” GW Pharmaceuticals plc (NASDAQ:GWPH) shares climbs 1.06% to $121.40 on Wednesday.
Technical Stock Analysis
Shares outstanding are recorded as 23.33 million and total shares floated are 18.96 million. Current ratio which is the relationship between current assets and current liabilities, indicating